Editas Medicine, Inc.Editas Medicine, Inc.E

Editas Medicine, Inc.

1.34USDR
−0.11−7.59%
Last update at Jan 9, 00:58 UTC
1.33USD
−0.01−0.75%
No tradesPre-marketLast update at 09:13 UTC
See on Supercharts

EDIT fundamentals

Key facts

Market capitalization‪110.61 M‬USD
Basic EPS (TTM)−2.56USD
Founded2013
CEOGilmore O’Neill
About

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Ownership
‪‪82.55 M‬‬
Free Float shares
‪‪81.78 M‬‬ (99.07%)
Closely held shares
‪‪770.84 K‬‬ (0.93%)
Free Float shares
‪‪81.78 M‬‬ (99.07%)
Closely held shares
‪‪770.84 K‬‬ (0.93%)
Capital structure
Market cap
‪‪110.61 M‬‬
Debt
‪‪38.49 M‬‬
Cash & equivalents
‪‪265.09 M‬‬
Enterprise value
‪‪−115.99 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪110.61 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.94x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.94x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪7.00‬
‪14.00‬
‪21.00‬
‪28.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−104,030.00%‬
‪−78,030.00%‬
‪−52,030.00%‬
‪−26,030.00%‬
‪−30.00%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−70.00 M‬‬
‪‪−35.00 M‬‬
‪0.00‬
‪‪35.00 M‬‬
‪‪70.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−75.00 M‬‬
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−63.00 M‬‬
‪‪−42.00 M‬‬
‪‪−21.00 M‬‬
‪0.00‬
‪‪21.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Genome Editing Technology
By country
Period: 2023
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪16.00 M‬‬
‪‪32.00 M‬‬
‪‪48.00 M‬‬
‪‪64.00 M‬‬
Actual
Estimate
Earnings
Next:Feb 26
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.84‬
‪−0.63‬
‪−0.42‬
‪−0.21‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

EDIT does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−70.00 M‬‬
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
‪‪210.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
‪‪210.00 M‬‬
‪‪280.00 M‬‬
Assets
Liabilities